ZFIN ID: ZDB-FISH-150901-3034
Fish name: fgf8ati282a/+
Genotype: fgf8ati282a/+
Targeting Reagent: none
HUMAN DISEASE MODELED by fgf8ati282a/+
No data available
GENE EXPRESSION
Gene expression in fgf8ati282a/+
RNA expression
Expressed Gene Structure Conditions Figures
col1a1a standard conditions Fig. 5 from Gebuijs et al., 2019
col1a2 standard conditions Fig. 5 from Gebuijs et al., 2019
col2a1a standard conditions Fig. 5Fig. 6. with image from Gebuijs et al., 2019
col9a1a standard conditions Fig. 5 from Gebuijs et al., 2019
col9a1b standard conditions Fig. 5 from Gebuijs et al., 2019
dlx2a standard conditions Fig. 5Fig. 6. with image from Gebuijs et al., 2019
dlx3b chemical treatment: SB 431542 Fig. 4 with image from Kwon et al., 2009
egr2b chemical treatment: SB 431542 Fig. 4 with image from Kwon et al., 2009
fgf8a standard conditions Fig. 5Fig. 6. with image from Gebuijs et al., 2019
foxi1 standard conditions Fig. 5 with image from Nechiporuk et al., 2007
chemical treatment: SB 431542 Fig. 4 with image from Kwon et al., 2009
fsta chemical treatment: SB 431542 Fig. 4 with image from Kwon et al., 2009
isl1a chemical treatment: SB 431542 Fig. 4 with image from Kwon et al., 2009
nkx3-2 standard conditions Fig. 5 from Gebuijs et al., 2019
pax2a standard conditions Fig. 5 with image from Nechiporuk et al., 2007
chemical treatment: SB 431542 Fig. 4 with image from Kwon et al., 2009
pax8 chemical treatment: SB 431542 Fig. 4 with imageFig. 5 with image from Kwon et al., 2009
runx2a standard conditions Fig. 5Fig. 6. with image from Gebuijs et al., 2019
runx2b standard conditions Fig. 5 from Gebuijs et al., 2019
shha chemical treatment: SB 431542 Fig. 4 with image from Kwon et al., 2009
sp7 standard conditions Fig. 5 from Gebuijs et al., 2019
Protein expression No data available
Reporter gene expression No data available
PHENOTYPE
Phenotype in fgf8ati282a/+
Phenotype Conditions Figures
branchiostegal ray 1 bone mineralization decreased occurrence, abnormal standard conditions Fig. 4 from Gebuijs et al., 2019
ceratobranchial 5 bone bone mineralization decreased occurrence, abnormal standard conditions Fig. 2. with imageFig. 4 from Gebuijs et al., 2019
ceratobranchial 5 tooth bone mineralization decreased occurrence, abnormal standard conditions Fig. 4 from Gebuijs et al., 2019
ceratohyal bone decreased length, abnormal standard conditions Fig. 3 from Gebuijs et al., 2019
chondrocranium bilateral symmetry, abnormal standard conditions Fig. 2 with image from Albertson et al., 2007
cleithrum bone mineralization decreased occurrence, abnormal standard conditions Fig. 4 from Gebuijs et al., 2019
embryonic viscerocranium morphogenesis process quality, normal control Fig. 9 with image from Lovely et al., 2016
embryonic viscerocranium morphogenesis process quality, normal chemical treatment: dorsomorphin Fig. 9 with image from Lovely et al., 2016
entopterygoid bone mineralization decreased occurrence, abnormal standard conditions Fig. 4 from Gebuijs et al., 2019
ethmoid cartilage decreased length, abnormal standard conditions Fig. 3 from Gebuijs et al., 2019
head decreased size, abnormal standard conditions Fig. 2. with imageFig. 3 from Gebuijs et al., 2019
head anterior region decreased width, abnormal standard conditions Fig. 3 from Gebuijs et al., 2019
Meckel's cartilage decreased length, abnormal standard conditions Fig. 3 from Gebuijs et al., 2019
Meckel's cartilage-palatoquadrate cartilage joint decreased width, abnormal standard conditions Fig. 3 from Gebuijs et al., 2019
notochord bone mineralization decreased occurrence, abnormal standard conditions Fig. 4 from Gebuijs et al., 2019
opercle bilateral symmetry, abnormal standard conditions Fig. 3 with image from Albertson et al., 2007
opercle malformed, abnormal standard conditions Fig. 3 with image from Albertson et al., 2007
opercle bone mineralization decreased occurrence, abnormal standard conditions Fig. 4 from Gebuijs et al., 2019
otic placode decreased amount, abnormal chemical treatment: SB 431542 Fig. 4 with image from Kwon et al., 2009
otic placode malformed, abnormal chemical treatment: SB 431542 Fig. 4 with image from Kwon et al., 2009
otic placode mislocalised medially, abnormal chemical treatment: SB 431542 Fig. 4 with image from Kwon et al., 2009
otic placode formation process quality, abnormal chemical treatment: SB 431542 Fig. 4 with image from Kwon et al., 2009
otic placode formation process quality, abnormal chemical treatment: SB 431542 Fig. 5 with image from Kwon et al., 2009
otic vesicle decreased amount, abnormal chemical treatment: SB 431542 Fig. 4 with image from Kwon et al., 2009
otic vesicle increased size, abnormal chemical treatment: SB 431542 Fig. 4 with image from Kwon et al., 2009
otic vesicle malformed, abnormal chemical treatment: SB 431542 Fig. 4 with image from Kwon et al., 2009
otic vesicle mislocalised medially, abnormal chemical treatment: SB 431542 Fig. 4 with image from Kwon et al., 2009
otolith bone mineralization decreased occurrence, abnormal standard conditions Fig. 4 from Gebuijs et al., 2019
parasphenoid bone mineralization decreased occurrence, abnormal standard conditions Fig. 2. with imageFig. 4 from Gebuijs et al., 2019
paraxial mesoderm mislocalised medially, abnormal chemical treatment: SB 431542 Fig. 4 with image from Kwon et al., 2009
paraxial mesodermal cell fate specification process quality, abnormal chemical treatment: SB 431542 Fig. 5 with image from Kwon et al., 2009
regulation of bone remodeling occurrence, abnormal standard conditions Fig. 5 with image from Albertson et al., 2007
ventral mandibular arch bilateral symmetry, abnormal standard conditions Fig. 2 with image from Albertson et al., 2007
ventral mandibular arch malformed, abnormal standard conditions Fig. 2 with imageFig. 5 with image from Albertson et al., 2007

CITATIONS  (9)